O. Smirnova, N. Vashakmadze, M. S. Karaseva, N. V. Zhurkova, A. Y. Rachkova, L. S. Namazova-Baranova
{"title":"儿童法布里病诊断和管理的现代方法","authors":"O. Smirnova, N. Vashakmadze, M. S. Karaseva, N. V. Zhurkova, A. Y. Rachkova, L. S. Namazova-Baranova","doi":"10.15690/vsp.v23i1.2652","DOIUrl":null,"url":null,"abstract":"Fabry disease (FD), or Andersen-Fabry disease, is a rare hereditary lysosomal disease (sphingolipids storage disease) characterized by progressive multisystem involvement. The major symptoms among children are neuropathic pain / acroparesthesia, angiokeratomas, hypo- or anhidrosis, vortex keratopathy. Biochemical tests, molecular genetic testing, and family screening play crucial role in the diagnosis of the disease. Specific pathogenetic treatment of FD includes enzyme replacement therapy (ERT) with recombinant medications of the lysosomal enzyme -galactosidase A. ERT initiation before the development of severe organs and systems’ damage contributes to its higher efficacy. This article covers various aspects of pathogenesis, clinical picture features in childhood, modern methods of diagnosis and management of FD according to literature data.","PeriodicalId":10867,"journal":{"name":"Current pediatrics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modern Approach to Fabry Disease Diagnosis and Management in Children\",\"authors\":\"O. Smirnova, N. Vashakmadze, M. S. Karaseva, N. V. Zhurkova, A. Y. Rachkova, L. S. Namazova-Baranova\",\"doi\":\"10.15690/vsp.v23i1.2652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Fabry disease (FD), or Andersen-Fabry disease, is a rare hereditary lysosomal disease (sphingolipids storage disease) characterized by progressive multisystem involvement. The major symptoms among children are neuropathic pain / acroparesthesia, angiokeratomas, hypo- or anhidrosis, vortex keratopathy. Biochemical tests, molecular genetic testing, and family screening play crucial role in the diagnosis of the disease. Specific pathogenetic treatment of FD includes enzyme replacement therapy (ERT) with recombinant medications of the lysosomal enzyme -galactosidase A. ERT initiation before the development of severe organs and systems’ damage contributes to its higher efficacy. This article covers various aspects of pathogenesis, clinical picture features in childhood, modern methods of diagnosis and management of FD according to literature data.\",\"PeriodicalId\":10867,\"journal\":{\"name\":\"Current pediatrics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pediatrics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15690/vsp.v23i1.2652\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15690/vsp.v23i1.2652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
法布里病(FD)或安德森-法布里病(Andersen-Fabry disease)是一种罕见的遗传性溶酶体疾病(鞘磷脂贮积病),以进行性多系统受累为特征。儿童的主要症状是神经性疼痛/痛觉过敏、血管角化瘤、脱水或缺水、涡状角膜病变。生化检测、分子基因检测和家族筛查在疾病诊断中起着至关重要的作用。FD 的特定发病机制治疗包括使用溶酶体酶-半乳糖苷酶 A 的重组药物进行酶替代治疗(ERT)。本文根据文献资料介绍了 FD 的发病机制、儿童期临床表现特征、现代诊断和管理方法等各个方面。
Modern Approach to Fabry Disease Diagnosis and Management in Children
Fabry disease (FD), or Andersen-Fabry disease, is a rare hereditary lysosomal disease (sphingolipids storage disease) characterized by progressive multisystem involvement. The major symptoms among children are neuropathic pain / acroparesthesia, angiokeratomas, hypo- or anhidrosis, vortex keratopathy. Biochemical tests, molecular genetic testing, and family screening play crucial role in the diagnosis of the disease. Specific pathogenetic treatment of FD includes enzyme replacement therapy (ERT) with recombinant medications of the lysosomal enzyme -galactosidase A. ERT initiation before the development of severe organs and systems’ damage contributes to its higher efficacy. This article covers various aspects of pathogenesis, clinical picture features in childhood, modern methods of diagnosis and management of FD according to literature data.